智通财经网·2026-03-23 09:33Core Viewpoint - The company has achieved an upgrade in its MSCI ESG rating from A to AA, establishing itself as a leader in ESG practices among global pharmaceutical companies [1][4]. Group 1: ESG Governance - The company has developed a comprehensive ESG governance system, with the board as the highest decision-making body, and has implemented the "CARE" strategy focusing on Cure, Accessible, Relationship, and Environmental aspects [1]. - The company integrates sustainable development principles into its decision-making and business operations [1]. Group 2: Environmental Responsibility - The company actively responds to China's "30·60" dual carbon goals, embedding green development concepts into its operations [2]. - It has been recognized as a green responsibility enterprise, being the first in the pharmaceutical industry to announce carbon neutrality goals, achieving over 10% annual reduction in major pollutant emissions for five consecutive years [2]. - The company aims to achieve simultaneous reductions in carbon emission intensity and total emissions by 2025, marking significant progress towards its carbon peak milestone [2]. - Three subsidiaries have been awarded national "green factory" titles, reflecting the company's commitment to green development [2]. Group 3: Social Responsibility - The company adheres to the operational philosophy of "health technology, warming more lives," focusing on international innovation strategies to enhance business and fill clinical gaps [3]. - Over the past three years, the company has invested more than RMB 13 billion in R&D, establishing an international R&D platform and acquiring innovative pharmaceutical companies to expand its pipeline [3]. - The company has served over 160 million patients with its key products in the last three years [3]. - It emphasizes talent development through initiatives like the Employee Assistance Program (EAP) and has donated over RMB 150 million to charitable causes in the past three years [3]. Group 4: Future Outlook - The upgrade to AA rating signifies high recognition of the company's ESG management and practices, marking a milestone in its commitment to sustainable development and corporate social responsibility [4]. - The company aims to continue deepening its practices across environmental, social, and governance dimensions while leading the industry towards collaborative development [4]. - It seeks to promote high-quality, sustainable development in China's pharmaceutical health industry, creating shared value for stakeholders and establishing itself as a global ESG benchmark [4].